NCT04940676 is a Phase 2 clinical trial of Huzhangxiefei Decoction in Acute Lung Injury, sponsored by Xinhua Hospital, Shanghai Jiao Tong University School of Medicine.

Who is sponsoring NCT04940676?

NCT04940676 is sponsored by Xinhua Hospital, Shanghai Jiao Tong University School of Medicine.

What drugs are being tested in NCT04940676?

Interventions in NCT04940676: Huzhangxiefei Decoction, 10% Huzhangxiefei Decoction.

What condition does NCT04940676 study?

NCT04940676 studies Acute Lung Injury, Sepsis.

Is NCT04940676 still recruiting?

NCT04940676 is currently status unknown. Last updated 26 November 2021.

Last reviewed 2021-11-26 · How we verify

NCT04940676

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Oral Administration or Nasal Feeding of Huzhangxiefei Decoction for Treatment in Sepsis Induced Acute Lung Injury

Status unknown Phase 2 Last updated 26 November 2021

What this trial tests

Phase 2 trial testing Huzhangxiefei Decoction in Acute Lung Injury in 58 participants. Status unknown.

Timeline

10 March 2021

Primary endpoint
30 November 2022

31 December 2022

Quick facts

Lead sponsor	Xinhua Hospital, Shanghai Jiao Tong University School of Medicine
Phase	Phase 2
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	double
Primary purpose	treatment
Enrollment	58
Start date	10 March 2021
Primary completion	30 November 2022
Estimated completion	31 December 2022
Sites	1 location across China

Drugs / interventions tested

Huzhangxiefei Decoction — full drug profile →
10% Huzhangxiefei Decoction — full drug profile →

Conditions studied

Acute Lung Injury — all drugs for Acute Lung Injury →
Sepsis — all drugs for Sepsis →

Sponsor

Xinhua Hospital, Shanghai Jiao Tong University School of Medicine

Who can join

18 and older, any sex, with Acute Lung Injury or Sepsis. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Hypothesis 1A: Oral Administration or Nasal Feeding of Huzhangxiefei Decoction will significantly attenuate sepsis-induced systemic organ failure as measured by overall response rate. Hypothesis 1B: Oral Administration or Nasal Feeding of Huzhangxiefei Decoction will attenuate sepsis-induced lung injury as assessed by the respiratory rate and oxygenation index. Hypothesis 1C: Oral Administration or Nasal Feeding of Huzhangxiefei Decoction will attenuate sepsis-induced lung injury as assessed by chest x-ray scale score, Chinese Medicine scale score. Hypothesis 1D: Oral Administration or Nasal Feeding of Huzhangxiefei Decoction will attenuate biomarkers of inflammation (C-Reactive Protein, Procalcitonin), vascular injury (Thrombomodulin, Angiopoietin-2), alveolar epithelial injury (Receptor for Advanced Glycation Products), while inducing the onset of a fibrinolytic state (Tissue Factor Pathway Inhibitor).

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Acute Lung Injury

Currently open trials in the same condition.

NCT05704166 — PirfenidoneVsPlacebo as Prophylaxis Against Acute Radiation-induced Lung Injury Following HFRT in Breast Cancer Patients · Phase 2 · recruiting

Other Xinhua Hospital, Shanghai Jiao Tong University School of Medicine trials

Trials by the same sponsor.

NCT07506811 — Effects of Different Music Tempos on Feeding Outcomes in Preterm Infants · NA · not yet recruiting
NCT07441187 — Efficacy and Safety of Henagliflozin, Retagliptin, and Metformin Extended-Release Tablets in Chinese Patients With Type · not yet recruiting
NCT07375602 — A Multimodal AI Prediction Model for Complications After Transcatheter Closure of Perimembranous VSD in Children · recruiting
NCT07405658 — Clinical Study on an Artificial Intelligence-Assisted Chest Radiograph Model Based on Big Data and Deep Learning for Ear · not yet recruiting
NCT07381400 — Neoadjuvant mFOLFOX6 Chemotherapy Combined With Anti-PD-1 Therapy in MSS/pMMR Locally Advanced Rectal Cancer (FIRM02 Stu · Phase 2 · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04940676 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Xinhua Hospital, Shanghai Jiao Tong University School of Medicine
Last refreshed: 26 November 2021

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04940676.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing